Inven2’s Board of Directors

Tom Pike is a life science industry professional holding board positions and other engagements related to the field. For many years he has worked to promote the health Industry in Norway, e.g. as co-initiator and member of the Norwegian governmental HealthCare21 Strategy Council, contributing to the BioVerdi report, mentor in the UiO SPARK program, etc.

He has over 30 years of experience in the health industry, including global responsibilities at Roche in Switzerland and as CEO of Roche Norway, Partner at the venture capital fund NeoMed and Chairman of the pharmaceutical industry association (LMI). For the past 13 years, the main focus has been on start-up companies in Norway and Sweden. He combines his board positions and consulting work with a part-time engagement at Oslo Metropolitan University working with innovation infrastructure. Tom Pike holds a B.Sc. Honors in pharmacology and has participated in a number of educational programs in business & administration, sales & marketing and finance.

Jens Petter Berg has been a professor of medicine (clinical biochemistry) at the University of Oslo (UiO) since 2007. From 1 August 2025 he will be Vice-Rector at UiO with special responsibilities for research and innovation in health and life sciences and the interaction with the university hospitals. He is a medical doctor by education (1986), a specialist in medical biochemistry (2004) and holds an adjunct position as a consultant at the Department of Medical Biochemistry at Oslo University Hospital. Berg holds a PhD from UiO (1995).

Berg has been Dean of Research at the Faculty of Medicine, UiO (2019-22), Head of Department at the Department of Medical Biochemistry, OUS (2015-19), Head of Research for the Division of Laboratory Medicine, OUS and UiO (2013-15). He has been Chairman of the Board of the Norwegian Centre for Molecular Medicine (NCMM) (2018-2024). His research interests are in diabetes and endocrinology. He chairs the expert council for the Norwegian Pediatric Diabetes Registry and is a member of the Norwegian Directorate of Health’s expert council for diagnostics and treatment of diabetes. Berg is editor-in-chief of the scientific journal The Scandinavian Journal of Clinical and Laboratory Investigations.

Erlend B. Smeland is director of research, innovation and education at Oslo University Hospital and professor at the University of Oslo. He is a group leader at the Centre for Cancer Biomedicine at the University of Oslo.

He has been Head of department at the Institute for Cancer Research at Oslo university Hospital and Head of Research in the South-Eastern Norway Regional Health Authority. Erlend B. Smeland is a member of the Board of Directors of the Norwegian Radium Hospital Research Foundation. In 2004, Erlend B. Smeland received King Olav V’s Cancer Research Award.

Mona-Elisabeth Rootwelt-Revheim is the head of the Department of Intervention at Oslo University Hospital and a professor at the Institute of Clinical Medicine at the University of Oslo. The Intervention Center is a research and development department focusing on research-driven innovation in collaboration with the industry, and the center has reported nearly 100 DOFIs related to medical technology in the last ten years.

Rootwelt-Revheim is an active researcher, primarily within basic and clinical studies related to technological translational research and radiotheranostics. She is a specialist in nuclear medicine and has previously been the head of Section for Nuclear Medicine at Oslo University Hospital. She collaborates particularly closely with the University of Pennsylvania after a research stay there in 2019.

She holds a master’s degree in health administration and has completed a research leadership program at the University of Oslo. Additionally, she has been the leader of the Professional Association in the Norwegian Medical Association and has held several other positions.

She has experience as a board member in both listed and unlisted companies.

Inger Sandlie is professor of molecular biology and deputy director of the Center for Immune Regulation, University of Oslo. She has a PhD from the University of Bergen and did postdocs at Johns Hopkins University, USA, and the Norwegian National Cancer Hospital.

She heads an active research group and is co-inventor of more than 10 patents that describe the production and use of modified antibodies and albumin. Furthermore, she is co-founder of two biotechnology companies, Vaccibody A/S and Nextera A/S, and has an extensive research collaboration with Novozymes A/S. In 2011, she received the first innovation prize awarded by the University of Oslo.

Idar Kreutzer is the Director of International, Private Ownership, and Digitalization in Public and Private Sectors at NHO. He previously served as the CEO of Finance Norway. From 2000 to 2012 he was the CEO of Storebrand ASA. Mr. Kreutzer is the Chairman of the Board of Aschehoug Forlag. He is a member of the Board of the University of Oslo, and a member of the Advisory Board of NHH Norwegian School of Economics.

In June 2018 Mr. Kreutzer handed over the financial sector’s Roadmap for Green Competitiveness on behalf of the entire Norwegian financial sector. In December 2017 Mr. Kreutzer was appointed by the Nordic Council of Ministers to evaluate the access to risk capital for companies in the Nordic region, and his report was launched in October 2018. In June 2015 until October 2016 Mr. Kreutzer was appointed member of The Norwegian Commission for Green Competitiveness by the Prime Minister of Norway. From December 2014 he has been a member of The Minister of Climate and Environment’s Climate Policy Council. In 2013 he was appointed member of the Strategy Council for the Norwegian Government Pension Fund Global. He has been a member of the World Business Council for Sustainable Development (WBCSD) and has Co-Chaired their Vision 2050. Mr. Kreutzer holds a MSc degree in Economics and Business Administration from the NHH Norwegian School of Economics.

Benedicte Bakke Agerup is currently the CEO of the investment companies Laho AS and Procerta AS. She has previously held the position of CFO in Wilh Wilhelmsen ASA and KLP Forsikring.

She has a degree in economics and business administration («siviløkonom ») from the Norwegian School of Economics (NHH) in Bergen, Norway and has completed the Advanced Management Program at Harvard Business School. She is an experienced board member and holds board memberships in both listed and unlisted companies and foundations.

Lars Kristian Eikvar is a medical doctor with a PhD in basic male reproductive endocrinology. He is a specialist in medical biochemistry and has worked on the implementation and application of biochemical markers for cardiac muscle damage and inflammation in atherosclerosis. After 12 years as a senior consultant at Ullevål University Hospital HF, he became the head of the Department of Medical Biochemistry at the merged Oslo University Hospital HF in 2010. From 2014 to 2019, he served as the clinic director for the Clinic for Diagnostics and Intervention, later the Clinic for Laboratory Medicine at the same institution. This position was combined with a role at the University of Oslo and leadership responsibility for the hospital’s largest university clinic.

He earned an Executive Master of Management from BI in 2012 and completed the National Executive Leadership Program for Health Enterprises. Additionally, he has served as chair of the Norwegian Association of Senior Hospital Physicians, as a central board member, and has held numerous other positions of trust within the Norwegian Medical Association. He has also been a board member of Helse Sør-Øst RHF and has held board positions in other foundations and limited companies. Lars Eikvar is currently the divisional director for research and diagnostics at Helse Sør-Øst RHF.

Anne Marie is an employee-elected board member.